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DObjective: Left ventricular hypertrophy regression is assumed to be one of the most important goals after aortic
valve replacement for aortic stenosis. Amoderate decrease in the glomerular filtration rate is associated with a sig-
nificantly increased risk of left ventricular hypertrophy in hypertensive patients. The effect of moderate kidney
disease on left ventricular hypertrophic remodeling in other conditions of chronic left ventricular pressure
overload, such as aortic stenosis, remains unknown. Therefore we tested the hypothesis that moderate chronic
kidney disease affects left ventricular mass regression in patients undergoing isolated aortic valve replacement
for aortic stenosis.
Methods: In 157 patients with aortic stenosis, left ventricular mass regression was assessed at 18 months after
aortic valve replacement. Among them, 73 (46%) had a moderate chronic kidney disease (glomerular filtration
rate between 60 and 30 mL/min per 1.73 m2). Patients with severely impaired kidney function (glomerular
filtration rate of<30 mL/min per 1.73 m2) were excluded.
Results: After surgical intervention, left ventricular mass was significantly lower from baseline value in both
groups, but patients with moderate chronic kidney disease continued to show an increased left ventricular
mass (61  18 vs 50  16 g/m2.7, P ¼ .0001). The baseline glomerular filtration rate was significantly related
to left ventricular mass at 18 months after surgical intervention (b¼0.17, r2¼ 0.45, P¼ .01) and left ventricular
mass absolute (b ¼ 0.18, r2 ¼ 0.19, P ¼ .03) and relative (b ¼ 0.20, r2 ¼ 0.21, P ¼ .02) regression. These
associations persisted after adjusting for confounding factors, including hypertension and patient–prosthesis
mismatch. After a mean time of 34  12 months from surgical intervention, congestive heart failure symptoms
developed mainly in subjects with moderate chronic kidney disease (adjusted hazard ratio, 1.9; 95% confidence
interval, 1.2–3.9; P ¼ .035).
Conclusions: Patients with aortic stenosis with concomitant moderate chronic kidney disease present a less
evident left ventricular mass regression after aortic valve replacement. Moreover, this condition is related to
an increased occurrence of congestive heart failure after surgical intervention. (J Thorac Cardiovasc Surg
2010;139:881-6)Left ventricular (LV) hypertrophy usually occurs in patients
with aortic valve stenosis as a consequence of chronic pres-
sure overload. LV mass regression is assumed to be one of
the most important goals after aortic valve replacement
(AVR) because residual LV hypertrophy is associated with
an increased rate of adverse events, such as myocardial in-
farction, sudden or arrhythmic death, and congestive heart
failure.1 However, a large number of patients continue to
show some degree of LV hypertrophy after surgical inter-
vention. Factors affecting normalization of LV mass
are not completely understood and include uncontrolled
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The Journal of Thoracic and CaHowever, these associations are not always consistent,4,5
suggesting that such aspects cannot fully explain residual
LV hypertrophy.
LV hypertrophy severity has been shown to be strongly
related to renal function in hypertensive patients.6 An inde-
pendent relationship between indicators of renal function
and LVmass is present even in subjects with apparently nor-
mal renal function. It is well established in patients with
chronic kidney disease (CKD) that there is a continuous in-
verse relationship between LV mass and glomerular filtra-
tion rate (GFR), regardless of hemodynamic overload. In
this respect sodium retention and the attendant/associated
alteration in the renin–angiotensin–aldosterone system
(RAAS) and sympathetic overactivity are important causa-
tive mechanism of LV hypertrophy.7
Nowadays, patients coming to AVR for aortic stenosis are
more frequently older and more likely to present with some
degree of kidney dysfunction. Detailed analysis of the asso-
ciation between renal function and LV mass in patients with
aortic stenosis undergoing AVR might provide useful infor-
mation to redefine risk stratification and generate hypothesesrdiovascular Surgery c Volume 139, Number 4 881
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DAbbreviations and Acronyms882ACEI/ARB ¼ angiotensin-converting
enzyme inhibitors/angiotensin
receptor blockers
AVR ¼ aortic valve replacement
CKD ¼ chronic kidney disease
EOA ¼ effective orifice area
GFR ¼ glomerular filtration rate
LV ¼ left ventricular
PPM ¼ patient–prosthesis mismatch
RAAS ¼ renin–angiotensin–aldosterone
systemto better understand factors influencing LV hypertrophy re-
gression after surgical intervention. Therefore we tested the
hypothesis that a moderate decrease in kidney function af-
fects LV mass regression in hospital survivors undergoing
AVR for aortic stenosis.
MATERIALS AND METHODS
We prospectively evaluated consecutive hospital survivors who under-
went isolated AVR for aortic valve stenosis (peak velocity,>3.5 m/s) in
one institution between May 2004 and July 2007. One hundred ninety-
four patients were screened. Exclusion criteria were concomitant native
aortic valve regurgitation more than moderate, concomitant coronary ar-
tery disease, previous cardiac surgery, and previous renal transplantation.
A creatinine-based equation for estimating the GFR was used to identify
patients with baseline impaired kidney function. For this purpose, the
4-variable Modification of Diet in Renal Disease equation was used,
as follows:
GFR ¼ 1863ðSCrÞ1:1543ðAgeÞ0:2033ð0:742 if femaleÞ
3ð1:212 if blackÞ:
Scr is serum creatinine value expressed in milligrams per deciliter.8 Accord-
ing to the current Kidney Disease Outcomes Quality Initiative guidelines,
moderate CKD was defined as a GFR between 60 and 30 mL/min per
1.73 m2, severely impaired kidney function was defined as a GRF between
30 and 15 mL/min per 1.73 m2, and established renal failure was defined as
a GFR of less than 15 mL/min per 1.73 m2.8 Because of the small number of
patients with baseline severely impaired kidney function (n¼ 10) and estab-
lished renal failure (n ¼ 2), they were not included.
Finally, the study population consisted of 157 patients. One hundred
forty of 157 received a bioprosthesis (Carpentier–Edwards Perimount Ma-
gna; Edwards Lifesciences LLC, Irvine, Calif); others had a mechanical
prosthesis (Carbomedics Standard Aortic Valve, Carbomedics Inc, Austin,
Tex, or St JudeMedicalMechanical Heart Valve Hemodynamic Plus Series,
St Jude Medical, St Paul, Minn). After surgical intervention, all patients
were periodically reviewed. At each follow-up visit, blood pressure was
measured 3 times in the left arm after the subjects had been at rest in the sit-
ting position for 5 minutes or longer, and the mean value of the 3 separate
systolic blood pressure and 3 separate diastolic blood pressure measure-
ments was used to determine the reported blood pressure in accordance
with the recent European Society of Hypertension and the European Society
of Cardiology Guidelines.9 Hypertensive therapy was instituted and eventu-
ally implemented to achieve a systemic blood pressure of less than 140/90
mm Hg. Uncontrolled hypertension was defined as systolic blood pressure
of 140 mmHg or greater or diastolic blood pressure of 90 mmHg or greater,The Journal of Thoracic and Cardiovascular Surgregardless of receiving antihypertensive medication.9 LV mass regression
was assessed by performing echocardiographic analysis preoperatively
and at 18 months after surgical intervention according to previous studies
showing a highly significant LV mass reduction during the first 18 months
after AVR and no further change in LV mass between 1.5 and 10 years.4
Thereafter, adverse events were ascertained by means of telephone inter-
views and hospital records.
Sudden death was defined as unexpected and otherwise unexplained
death within 1 hour from the onset of witnessed terminal symptoms or un-
explained death during sleep. Arrhythmic death was defined as death from
a cardiac rhythm disturbance requiring external defibrillation or pacing or
documented hemodynamically unstable cardiac arrhythmia. Congestive
heart failure was defined according to the Framingham clinical diagnostic
criteria.10
LV mass was calculated according to the European and American Asso-
ciations of Echocardiography guidelines11 and normalized by height2.7.12
LV hypertrophy was defined as an LV mass index of 50 g/m2.7 or greater
in men and 47 g/m2.7 or greater in woman.13 LV volumes were estimated
by using the z-derived method,14 and ejection fraction was calculated as
follows:
ðEnd--diastolic volumeEnd--systolic volumeÞ=End--diastolic volume:
The prosthesis valve effective orifice area (EOA) was derived from the
continuity equation: ðLVOT230:7853TVI1Þ=TVI2, where LVOT is the
diameter of the LV outflow tract and TVI1 and TVI2 are the time-velocity in-
tegrals at the LV outflow tract and across the aortic valve, respectively. The
meangradientwasmeasuredbymeans of continuous-waveDoppler echocar-
diographic analysis and the simplified Bernoulli equation. PPMwas defined
as anEOA indexed for body surface area of 0.85 cm2/m2 or less.3AllDoppler
measurements were obtained as the average of at least 3 cycles in patients
with sinus rhythm or more than 5 cycles in those with atrial fibrillation.
Differences in baseline characteristics stratified by moderate CKD were
compared by using the c2 test for categorical variables and the t test for con-
tinuous variables (log-transformed when required). LVmass regression was
assessed in terms of indexed LV mass at 18 months after surgical interven-
tion, absolute LV mass regression (baseline indexed LV mass minus in-
dexed LV mass at 18 months after surgical intervention), and relative LV
mass regression (absolute LV mass regression/baseline indexed LV
mass). Pearson’s correlation coefficient was used to evaluate the correlation
between LV mass regression and individual estimated GFR. A multivariate
linear regression was performed to assess the independent value of GFR on
LV mass regression, adjusting for clinical variables selected on the basis of
face validity that were associated with GFR at a P value of less than .05.
Cumulative event-free survival was measured by using the Kaplan–
Maier method, and unadjusted differences were compared with the log-rank
test. Cox proportional hazards regressionwas used to assess the independent
effect of moderate CKD on the outcome of interest, adjusting for clinical
variables associated at a P value of less than .1. Before inclusion, these
were assessed for association (if showing parallel regression lines [ie, colin-
earity]) and tested by using a stepwise forward selective procedure. If 2 or
more variables were associated with each other, only the variable showing
the strongest relationshipwas included, and the others were discarded. In the
multivariate linear regression analysis data were expressed as regression co-
efficients (b), determination coefficients (r2), and P values.
Statistical analysis was performed with the Statistical Package for the
Social Sciences, version 11 (SPSS, Inc, Chicago, Ill). The authors had
full access to the data and take responsibility for their integrity. All authors
have read and agreed to the report as written.RESULTS
Baseline mean GFR was 62  21 mL/min per 1.73 m2.
According to the definition given in the Methods section,
moderate CKD was present in 73 (46%) of 157 patients.ery c April 2010
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DSubjects with moderate CKD were older and more likely to
be female. Baseline indexed LV mass and LV hypertrophy
occurrence were significantly increased in patients with
moderate CKD. Estimated GFR was inversely related to
baseline indexed LV mass (b ¼ 0.24, r2 ¼ 0.32, P ¼
.001). Native aortic valve stenosis severity and baseline
LV ejection fraction did not differ between the 2 groups. Im-
planted prosthesis size and type were similar in the 2 groups
(Table 1).
At 18 months after surgical intervention, indexed LV
mass was significantly less than the baseline value in both
groups, but patients with moderate CKD continued to
show an increased indexed LV mass when compared with
patients with preserved kidney function. Consequently, the
continued prevalence of LV hypertrophy remained higher
in the moderate CKD group. No relevant differences were
found in mean prosthesis indexed EOA and PPM occurrence
(Table 1). Of note, despite medical therapy, uncontrolledTABLE 1. Baseline, operative, and 18-month follow-up data stratified for
No CKD (n ¼
Baseline data
Mean age (y) 68  11
Female sex (%) 34
Baseline hypertension (%) 45
Diabetes (%) 25.0
Congestive heart failure (%) 43
Mean GFR (mL/min per 1.73 m2) 78  13
Atrial fibrillation (%) 15.5
Mean transvalvular peak gradient (mm Hg) 80  26
Mean aortic valve area (cm2) 0.75  0.1
Mean LV ejection fraction (%) 64  10
Mean LV mass index (g/m2.7) 63  19
LV hypertrophy (%) 69.6
Operative data
Bioprosthesis (%) 87
Mean prosthesis size (mm) 21.09  1.8
Mean aortic crossclamp time (min) 85  20
Mean cardiopulmonary bypass time (min) 101  31
18-mo Follow-up data
Uncontrolled hypertension (%) 27.8
Medication use
ACEI (%) 50
ARB (%) 9.5
b-blockers (%) 23.8
Mean GFR (mL/min per 1.73m2) 80  12*
Mean LV ejection fraction (%) 68  12
Mean LV mass index (g/m2.7) 50  26z
LV hypertrophy (%) 35.0
Mean transprosthesis peak gradient (mm Hg) 19  11
Mean prosthesis EOA (cm2) 1.35  0.33
Mean indexed EOA (cm2/m2) 0.87  0.18
PPM (%) 36.6
CKD, Chronic kidney disease; GFR, glomerular filtration rate; LV, left ventricular; ACEI, an
fective orifice area; PPM, patient–prosthesis mismatch. *P ¼ .33 when compared with base
zP ¼ .0003 when compared with baseline values (paired t test). xP ¼ .006 when compared
The Journal of Thoracic and Cahypertension occurred, with no differences between the 2
groups. Patients with CDK were also more likely to use b-
blockers, but no differences existed for angiotensin-convert-
ing enzyme inhibitors/angiotensin receptor blockers (ACEI/
ARB) use. Mean GFR did not significantly differ from pre-
operative values. Baseline estimated GFR was significantly
related to LV mass/m2.7 at 18 months after surgical interven-
tion (Figure 1) and LV mass/m2.7 absolute and relative re-
gression, and these associations persisted after adjusting
for baseline LV mass/m2.7, female sex, uncontrolled hyper-
tension, PPM, and ACEI/ARB use (Table 2).
Clinical follow-up was completed for all patients after
amean of 34 12months.During the study period, 6 patients
died (3 in each group). Therewere 2 sudden deaths, 1 arrhyth-
mic death, 1 end-stage congestive heart failure death, 1 fatal
stroke, and 1 pneumonia-related death. Nonfatal acute myo-
cardial infarction occurred in 2 cases (both in the moderate
CKD group). Kaplan–Meier analysis showed a decreasedmoderate CKD occurrence
84) Moderate CKD (n ¼ 73) P value
73  8 .0007
50 .06
59 .11
26.0 .967
52 .33
45  12 <.0001
13.7 .92
81  29 .75
0.73  0.1 .21
65  8 .60
71  18 .01
90.2 .003
92 .3
6 20.75  1.94 .26
91  23 .08
111  41 .08
30.1 .88
53.4 .79
16.4 .29
41.1 .03
46  12y <.0001
66  1 .22
61  25x .0001
58.6 .006
20  11 .57
1.27  0.39 .16
0.84  0.2 .32
40.1 .77
giotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; EOA, ef-
line values (paired t test). yP ¼ .59 when compared with baseline values (paired t test).
with baseline values (paired t test).
rdiovascular Surgery c Volume 139, Number 4 883
FIGURE 1. The relationship between indexed left ventricular (LV)mass at
18 months after surgical intervention and baseline glomerular filtration rate
(GFR) is presented graphically (regression equation: y ¼ 67.50.172 x).
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Dcongestive heart failure–free survival in patients with moder-
ate CKD (unadjusted hazard ratio, 2.3; 95% confidence inter-
val, 1.3–3.5; P ¼ .03; Figure 2). After adjusting for
preoperative congestive heart failure, LV ejection fraction,
baseline LV mass/m2.7, PPM, uncontrolled hypertension,
and ACEI/ARB use, moderate CKD disease remained an in-
dependent predictor of congestive heart failure (adjusted haz-
ard ratio, 1.9; 95% confidence interval, 1.2–3.9; P ¼ .035).DISCUSSION
The principal result of this observational study was that
patients with aortic stenosis with concomitant moderately
impaired kidney function presented with a higher baseline
LV mass and less evident LV hypertrophy regression after
AVR. These associations were independent from the occur-
rence of uncontrolled hypertension and PPM.
Post-AVR residual hypertrophy is a complex phenome-
non, and it still represents a vexing problem that has an effect
on morbidity and mortality. There is no doubt that hemody-
namic factors, such as uncontrolled blood pressure, have an
important effect on residual LV hypertrophy, but other fac-TABLE 2. Correlations between baseline glomerular filtration rate expr
regression
Model Indexed LV mass at 18 mo
Unadjusted b ¼0.17
r2 ¼ 0.45
P ¼ .01
Adjusted for Female sex
Baseline indexed LV mass b ¼0.12
Uncontrolled hypertension r2 ¼ 0.31
PPM P ¼ .03
ACEI/ARB use
LV, Left ventricular; PPM, patient–prosthesis mismatch; ACEI, angiotensin-converting enz
884 The Journal of Thoracic and Cardiovascular Surgtors regulating the growth of LV mass might influence the
post-AVR remodeling process.
Moderate CKD and LV Hypertrophy
LV hypertrophy is frequently observed in patients with
end-stage renal failure and is an independent predictor of
cardiovascular mortality and heart failure.15 Recent studies
have shown that even a moderate decrease in GFR is associ-
ated with a significantly increased risk of LV hypertrophy,
regardless of blood pressure control and other traditional
risk factors.6 That estimated GFR is an independent determi-
nant of LVmass indicates that decreased kidney function per
se contributes to LV hypertrophy. This association has been
observed in a cohort of unselected middle-aged patients with
hypertension,6 and no previous study investigated the effect
of moderate CKD on LV hypertrophic remodeling in other
conditions of chronic LV pressure overload, such as aortic
stenosis.
Aortic stenosis is rapidly becoming a typical disease of
aging, with an increasing number of patients presenting
with some degrees of concomitant kidney dysfunction. In
the present study we were able to demonstrate that moderate
reduction of kidney function is a frequent event in patients
undergoing AVR for aortic stenosis; these patients had an
increased preoperative LV mass and showed a reduced LV
mass regression after surgical intervention. In addition, sub-
jects with moderate CKD had an increased risk of congestive
heart failure symptoms after surgical intervention, and this
might be partially explained by their increased LV mass.15
The lack of LV hypertrophy regression after AVR for aor-
tic stenosis has been long considered a pure consequence of
hemodynamic overload because of uncontrolled hyperten-
sion2 or PPM.3 However, some studies have suggested that
pressure overload per se did not completely account for the
increased LV mass,4,5 and the extent of its regression after
the removal of the hemodynamic trigger seems to be influ-
enced by the presence of presumably irreversible myocyte
abnormalities occurring in the context of marked hypertro-
phic processes.1,4,5 As shown in hypertensive patients, mod-
erate impaired kidney function exacerbates the hypertrophic
adaptive process to pressure overload.6 In the presence ofessed as milliliters per minute per 1.73 m2 and indexes of LV mass
LV mass absolute regression LV mass relative regression
b ¼ 0.18 b ¼ 0.20
r2 ¼ 0.19 r2 ¼ 0.21
P ¼ .03 P ¼ .02
b ¼ 0.21 b ¼ 0.22
r2 ¼ 0.23 r2 ¼ 0.20
P ¼ .02 P ¼ .01
yme inhibitor; ARB, angiotensin receptor blockers.
ery c April 2010
FIGURE 2. Congestive heart failure–free survival according to the pres-
ence of baseline moderate chronic kidney disease (CKD; hazard ratio,
2.3; 95% confidence interval, 1.3–3.5; P ¼ .03).
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change, thus affecting LV mass regression after AVR.
Aortic stenosis–related LV hypertrophy in patients with
moderate CKD can be enhanced by several mechanisms in-
volving sodium retention and neurohumoral factors, such
as activation of the RAAS.16 There is increasing evidence
to suggest that angiotensin II might directly contribute to
the development of LV hypertrophy through its growth fac-
tor properties on smooth muscle cells and cardiac myo-
cytes.17 Angiotensin II plays a role in cardiac fibrosis by
stimulating transforming growth factor b1 gene expression
and induction of fibroblast proliferation and collagen deposi-
tion.18 In addition, chronic renal disease is associated with
a sympathetic overactivity. It has been hypothesized that
the sympathetic nervous system might interact with the
RAAS19 and contribute to the development and progression
of LV hypertrophy. Finally, secondary hyperparathyroidism
related to moderately impaired kidney function might con-
tribute to the LV hypertrophic process.20 In fact, parathyroid
hormone receptors have been demonstrated to induce hyper-
trophy of myocytes.
This study has some limitations. Although we identified
the association between baseline GFR and LV mass regres-
sion, causality cannot be proved. Because of the few late
deaths recorded, we cannot draw any conclusions about the
effect of moderate CKD on overall or cardiac mortality after
AVR. Finally, the definition of LV hypertrophy we adopted
was obtained from studies in the general population, and it is
poorly applied to patients with surgical aortic valve stenosis.
Therefore we analyzed the relationship between kidney func-
tion and LV hypertrophy by using LV mass as a continuous
variable. We used indexation by body height because it was
suggested to be more appropriate for patients with CKD.13Clinical Implications
Our results strengthen the usefulness of routinely deter-
mining GFR in patients with aortic stenosis not only toThe Journal of Thoracic and Caevaluate renal function but also to stratify their cardiovascu-
lar risk. These patients are suggested to be characterized by
a marked hypertrophic myocardial response to the increased
afterload and delayed LV reverse remodeling after AVR.
For these patients, the opportunity of an earlier operation
to prevent the irreversible myocardial changes related to
marked LV hypertrophic process and to reduce the risk of
residual LV hypertrophy should be investigated. In addition,
the importance of the RAAS in mediating cardiac hypertro-
phy in patients with CKD strengthens the usefulness of
routine angiotensin-converting enzyme inhibitor use in this
high-risk subgroup regardless of blood pressure control
and suggests the potential role of type 1 angiotensin II recep-
tor antagonists to completely inhibit the action of angioten-
sin II in this setting.9 Further investigations are required to
confirm our findings.References
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